ChronoScale (CHRN) Q4 2025 earnings summary

Executive summary

• Revenue for 2025 was $12.8 million, down 29% year-over-year, primarily due to lower Enterprise Health device sales in EMEA, partially offset by increased Personal Health device sales in the Americas.

• Net loss for 2025 was $11.7 million, compared to $11.3 million in 2024, reflecting continued operating losses and impairment charges.

• Gross margin remained steady at 53% year-over-year.

• The company entered into a business combination agreement with Applied Digital Cloud, expected to close in Q2 2026, after which the company will be renamed ChronoScale Corporation.

• A $5.3 million private placement was completed in January 2026 to support working capital.

Financial highlights

• Revenue: $12.8 million in 2025, down from $17.9 million in 2024.

• Gross profit: $6.8 million in 2025, down from $9.5 million in 2024.

• Net loss: $11.7 million in 2025, compared to $11.3 million in 2024.

• Operating expenses: $20.2 million in 2025, up slightly from $20.0 million in 2024.

• Cash at year-end: $1.2 million, with working capital of $5.4 million.

Outlook and guidance

• Management expects continued operating losses and negative cash flows, with substantial doubt about the ability to continue as a going concern without additional financing.

• Majority of 2026 revenue is expected from Enterprise Health, but Personal Health sales are anticipated to grow quarter over quarter.

• The business combination with Applied Digital Cloud is expected to close in Q2 2026, subject to customary conditions.